MC2 Therapeutics

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a licensing agreement with Denmark-headquartered MC2 Therapeutics A/S, securing exclusive development and commercialization rights to MC2’s Wynzora cream, a therapy for plaque psoriasis. The agreement covers the Greater China territory, which includes mainland China, Hong Kong, Macau, and Taiwan. Financial Terms…